Dengue virus
| Anisomycin | DENV-4 | DNA synthesis inhibitor | Preclinical | — | Human ribosome | |
| Azauridine | DENV-4 | Nucleoside analog | Preclinical | — | Viral RNA pol | |
| Betulinic Acid | DENV-4 | Unknown | Preclinical | — | Unknown | |
| Fenretinide | DENV-4 | Unclear | Preclinical | — | Human RAR | |
| Glycyrrhizin | DENV-4 | 0 | Preclinical | — | Human TNF | |
| Metformin | DENV-4 | AMPK activator | Preclinical | — | Human PTK | |
| Minocycline | DENV-4 | Inhibition of autophagy | Preclinical | — | Human MIF | |
| Posaconazole | DENV-4 | Inhibition of OSBP and ORP4; Inhibition of viral organelle formation | Preclinical | — | Human lipid transfer protein | |
| Ribavirin | DENV-4 | Nucleoside inhibitor; Guanosine (ribonucleic) analog | Approved (other) | Japan | Viral RNA pol | |
| Sunitinib | DENV-4 | Broad TK inhibitor | Preclinical | — | Human PTK | |
| Suramin | DENV-4 | Prevent viral RNA replication | Preclinical | — | Viral Helicase |